Skip to main content

Advertisement

SpringerLink
Log in

Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment

  • Leukemia (A Aguayo, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This manuscript aims at updating the knowledge on the clinico-biological characteristics, pathogenesis, and the diagnostic challenges of T-LGLL and CLPD-NK disorders and reviews the advances in the management and treatment of these patients.

Recent Findings

It has been shown that clonal large granular lymphocyte (LGL) expansions arise from chronic antigenic stimulation, leading to resistance to apoptosis.

Summary

All the above findings have facilitated the diagnosis of LGLL and provided insights in the pathogenesis of the disease. At present, there is no standard first-line therapy for the disease. Immunosuppressive agents are the treatment routinely used in clinical practice. However, these agents have a limited capacity to eradicate the LGL clone and induce long-lasting remission. Advances in the knowledge of pathogenesis have made it possible to explore new therapeutic targets with promising results. Since LGLL is a rare disease, international efforts are needed to carry on prospective clinical trials with new potentially active drugs that could include a large number of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Loughran TP Jr, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, Lum LG, Slichter SJ. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102(2):169–75. https://doi.org/10.7326/0003-4819-102-2-169.

    Article  PubMed  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017.

    Google Scholar 

  3. Shah MV, Hook CC, Call TG, Go RS. A population-based study of large granular lymphocyte leukemia. Blood Cancer J. 2016;6(8):e455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dinmohamed AG, Brink M, Visser O, Jongen-Lavrencic M. Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013. Leukemia. 2016;30(6):1449–51.

    Article  CAS  PubMed  Google Scholar 

  5. Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma, Myeloma Leuk. 2012;12(6):400–5. https://doi.org/10.1016/j.clml.2012.06.006.

    Article  CAS  Google Scholar 

  6. Matutes E. Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. Expert Rev Hematol. 2017;10(3):251–8. https://doi.org/10.1080/17474086.2017.1284585.

    Article  CAS  PubMed  Google Scholar 

  7. Lamy T, Moignet A, Loughran TP. LGL leukemia: from pathogenesis to treatment. Blood. 2017;129(9):1082–94.

    Article  CAS  PubMed  Google Scholar 

  8. Moignet A, Lamy T. Latest advances in the diagnosis and treatment of large granular lymphocytic leukemia. Am Soc Clin Oncol Educ B. 2018;(38):616–25. Comprehensive reviews on management of LGLL in the current practice.

    Article  Google Scholar 

  9. Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG, Jerez A, Thota S, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018;59(2):416–22. https://doi.org/10.1080/10428194.2017.1339880. Retrospective study that includes 204 patients diagnosed with LGLL. This paper provides clinical and laboratory data.

    Article  PubMed  Google Scholar 

  11. Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, et al. Large granular lymphocytic leukemia – a retrospective study of 319 cases. Am J Hematol. 2021;96(7):772–80. Retrospective study that includes 319 patients diagnosed with LGLL. This paper provides clinical and laboratory data and it is the largest series of LGLL published recently.

    Article  CAS  PubMed  Google Scholar 

  12. Loughran TP. Clonal diseases of large granular lymphocytes. Blood [Internet]. 1993;82(1):1–14. https://doi.org/10.1182/blood.V82.1.1.bloodjournal8211.

    Article  Google Scholar 

  13. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89(1):256–60. https://doi.org/10.1182/blood.V89.1.256.

    Article  CAS  PubMed  Google Scholar 

  14. Watters RJ, Liu X, Loughran TP. T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma. 2011;52(12):2217–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Barilà G, Teramo A, Calabretto G, Vicenzetto C, Gasparini VR, Pavan L, et al. Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia. 2020;34(4):1116–24. https://doi.org/10.1038/s41375-019-0644-0. Study documenting the impact on overall survival of STAT3 mutations.

    Article  CAS  PubMed  Google Scholar 

  16. Viny A, Lichtin A, Pohlman B, Loughran T, Maciejewski J. Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma. 2008;49(5):932–8.

    Article  CAS  PubMed  Google Scholar 

  17. Poullot E, Zambello R, Leblanc F, Bareau B, De March E, Roussel M, et al. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Ann Oncol. 2014;25(10):2030–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rivero A, Mozas P, Jiménez L, López-Guerra M, Colomer D, Bataller A, et al. Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. Cancers (Basel). 2021 Aug 2;13(15):3900.

  19. Freimark B, Lanier L, Phillips J, Quertermous T, Fox R. Comparison of T cell receptor gene rearrangements in patients with large granular T cell leukemia and Felty’s syndrome. J Immunol. 1987;138(6):1724–9.

    CAS  PubMed  Google Scholar 

  20. Starkebaum G, Loughran TP Jr, Gaur LK, Davis P, Nepom BS. Immunogenetic similarities between patients with Felty’s syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1997;40(4):624–6. https://doi.org/10.1002/art.1780400406.

    Article  CAS  PubMed  Google Scholar 

  21. Bowman SJ, Sivakumaran M, Snowden N, Bhavnani M, Hall MA, Panayi GS, Lanchbury JS. The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty’s syndrome. Arthritis Rheum. 1994;37(9):1326–30. https://doi.org/10.1002/art.1780370909.

    Article  CAS  PubMed  Google Scholar 

  22. Zhang R, Shah MV, Loughran TP Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol. 2010;28(3):105–17. https://doi.org/10.1002/hon.917.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Semenzato G, Marino F, Zambello R. State of the art in natural killer cell malignancies. Int J Lab Hematol. 2012;34(2):117–28.

    Article  CAS  PubMed  Google Scholar 

  24. Teramo A, Barilà G, Calabretto G, Ercolin C, Lamy T, Moignet A, et al. STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget. 2017;8(37):61876–89.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, et al. Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. Br J Haematol. 2020;189(2):318–22.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sidiqi MH, Aljama MA, Viswanatha DS, Dingli D. T-cell large granular lymphocytic leukemia and plasma cell disorders. Haematologica. 2019;104(3):e108–10.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther. 2014;15(3):247–55.

    Article  CAS  PubMed  Google Scholar 

  28. Viny AD, Maciejewski JP. High rate of both hematopoietic and solid tumors associated with large granular lymphocyte leukemia. Leuk Lymphoma. 2015;56(2):503–4.

    Article  PubMed  Google Scholar 

  29. Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, et al. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016;30(5):1201–4.

    Article  CAS  PubMed  Google Scholar 

  30. Rossoff LJ, Genovese J, Coleman M, Dantzker DR. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia*: amelioration by cladribine therapy. Chest. 1997;112(2):551–3. https://doi.org/10.1378/chest.112.2.551 (ISSN 0012-3692).

    Article  CAS  PubMed  Google Scholar 

  31. Khalid S, Daw H, Jacob M, Nakashima M. T cell large granular lymphocytic leukemia with pulmonary hypertension. Gulf J Oncolog. 2018;1(26):72–4.

    PubMed  Google Scholar 

  32. Shi M, Olteanu H, Jevremovic D, He R, Viswanatha D, Corley H, et al. T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics. Mod Pathol. 2020;33(10):2046–57. https://doi.org/10.1038/s41379-020-0568-2.

    Article  CAS  PubMed  Google Scholar 

  33. Muñoz-García N, Jara-Acevedo M, Caldas C, Bárcena P, López A, Puig N, et al. STAT3 and STAT5B mutations in T/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): Association with disease features. Cancers (Basel). 2020;12(12):1–20. Study that analizes the association of STAT3/5B mutations with biological and clinical features of LGLL.

    Article  CAS  Google Scholar 

  34. Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128(20):2465–8. https://doi.org/10.1182/blood-2016-06-724856.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lamy T, Loughran TP. Natural killer (NK) cell large granular lymphocyte leukemia. Semin Hematol. 2003;40(3):185–95.

    Article  PubMed  Google Scholar 

  36. Sokol L, Loughran TP. L eukemias large granular lymphocyte leukemia. Oncologist. 2006;11(3):263–73.

    Article  CAS  PubMed  Google Scholar 

  37. Osuji N, Beiske K, Randen U, Matutes E, Tjonnfjord G, Catovsky D, et al. Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemia. Histopathology. 2007;50(5):547–54.

    Article  CAS  PubMed  Google Scholar 

  38. Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood. 2002;99(1):268–74.

    Article  CAS  PubMed  Google Scholar 

  39. Evans HL, Burks E, Viswanatha D, Larson RS. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol. 2000;31(10):1266–73.

    Article  CAS  PubMed  Google Scholar 

  40. Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118(16):4383–93.

    Article  CAS  Google Scholar 

  41. Zambello R, Semenzato G. Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Semin Hematol. 2003;40(3):201–12.

    Article  CAS  PubMed  Google Scholar 

  42. Zambello R, Falco M, Della Chiesa M, Trentin L, Carollo D, Castriconi R, et al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood. 2003;102(5):1797–805.

    Article  CAS  PubMed  Google Scholar 

  43. Fischer L, Hummel M, Burmeister T, Schwartz S, Thiel E. Skewed expression of natural-killer (NK)-associated antigens on lymphoproliferations of large granular lymphocytes (LGL). Hematol Oncol. 2006;24(2):78–85.

    Article  CAS  PubMed  Google Scholar 

  44. Epling-Burnette PK, Painter JS, Chaurasia P, Bai F, Wei S, Djeu JY, et al. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood. 2004;103(9):3431–9.

    Article  CAS  PubMed  Google Scholar 

  45. Scquizzato E, Teramo A, Miorin M, Facco M, Piazza F, Noventa F, et al. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia. 2007;21(5):1060–9.

    Article  CAS  PubMed  Google Scholar 

  46. Jerez A, Clemente MJ, Makishima H, Koskela H, LeBlanc F, Ng KP, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Epling-Burnette PK, Loughran TP. Survival signals in leukemic large granular lymphocytes. Semin Hematol. 2003;40(3):213–20.

    Article  CAS  PubMed  Google Scholar 

  48. Zambello R, Trentin L, Facco M, Cerutti A, Sancetta R, Milani A, et al. Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3+ granular lymphocytes. Cancer Res. 1995;55(24):6140–5.

    CAS  PubMed  Google Scholar 

  49. Wlodarski MW, Nearman Z, Jankowska A, Babel N, Powers J, Leahy P, et al. Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol. 2008;83(3):589–601.

    Article  CAS  PubMed  Google Scholar 

  50. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008;105(42):16308–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Zhang D, Loughran TP Jr. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program. 2012;2012:652–9. https://doi.org/10.1182/asheducation-2012.1.652.

    Article  PubMed  Google Scholar 

  52. Zambello R, Facco M, Trentin L, Sancetta R, Tassinari C, Perin A, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997;89(1):201–11. https://doi.org/10.1182/blood.V89.1.201.

    Article  CAS  PubMed  Google Scholar 

  53. Chen J, Petrus M, Bamford R, Shih JH, Morris JC, Janik JE, et al. Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia. Blood. 2012;119(1):137–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–13. https://doi.org/10.1056/NEJMoa1114885.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27(7):1598–600.

    Article  CAS  PubMed  Google Scholar 

  57. Rajala HLM, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, et al. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica. 2015;100(1):91–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Rajala HLM, Eldfors S, Kuusanmäki H, Van Adrichem AJ, Olson T, Lagström S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121(22):4541–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Rajala HLM, Mustjoki S. STAT5b in LGL leukemia - a novel therapeutic target? Oncotarget. 2013;4(6):808–9.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Dhodapkar M, Li C, Lust J, Tefferi A, Phyliky R. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994;84(5):1620–7.

    Article  CAS  PubMed  Google Scholar 

  61. Zambello R, Teramo A, Gattazzo C, Semenzato G. Are T-LGL leukemia and NK-chronic lymphoproliferative disorder really two distinct diseases? Transl Med @ UniSa. 2014;8(1):4–11.

    Google Scholar 

  62. Loughran TP, Zickl L, Olson TL, Wang V, Zhang D, Rajala HLM, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29(4):886–94.

    Article  CAS  PubMed  Google Scholar 

  63. Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood. 1996;87(3):1199–200.

    Article  CAS  PubMed  Google Scholar 

  64. Osuji N, Matutes E, Tjonnfjord G, Grech H, Del Giudice I, Wotherspoon A, et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer. 2006;107(3):570–8.

    Article  PubMed  Google Scholar 

  65. Fujishima N, Sawada KI, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555–9.

    Article  CAS  PubMed  Google Scholar 

  66. Loughran TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood. 1994;84(7):2164–70. https://doi.org/10.1182/blood.V84.7.2164.2164.

    Article  PubMed  Google Scholar 

  67. Go RS, Tefferi A, Li CY, Lust JA, Phyliky RL. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood. 2000;96(10):3644–6. https://doi.org/10.1182/blood.V96.10.3644.

    Article  CAS  PubMed  Google Scholar 

  68. Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014;28(5):1134–6.

    Article  CAS  PubMed  Google Scholar 

  69. Lamy T, Pastoret C, Houot R, Ysebaert L, Hunault M, Damaj G, et al. Prospective, multicentric phase II randomized trial comparing the efficacy of methotrexate or cyclophosphamide in large granular lymphocytic leukemia: a French national study. Report on the Interim Analysis. Blood 2019; 134 (Supplement_1): 1545. Ongoing prospective trial comparing the efficacy of metotrexate or cyclophosphamide as first-line therapy in LGLL.

    Article  Google Scholar 

  70. Tsirigotis P, Venetis E, Kapsimali V, Rontogianni D, Varvitsioti E, Pappa V, et al. 2-Deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leuk Res. 2003;27(9):865–7.

    Article  PubMed  Google Scholar 

  71. Fortune AF, Kelly K, Sargent J, O’Brien D, Quinn F, Chadwick N, et al. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma. 2010;51(5):839–45.

    Article  CAS  PubMed  Google Scholar 

  72. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12(12):2588–93. https://doi.org/10.1200/JCO.1994.12.12.2588.

    Article  CAS  PubMed  Google Scholar 

  73. Dincol G, Diz-Kuçukkaya R, Bicakci E. T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin. Neth J Med. 2008;66(2):85–7.

    CAS  PubMed  Google Scholar 

  74. Sternberg A, Eagleton H, Pillai N, Leyden K, Turner S, Pearson D, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol. 2003;120(4):699–701.

    Article  CAS  PubMed  Google Scholar 

  75. Tse E, Chan JCW, Pang A, Au WY, Leung AYH, Lam CCK, et al. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia. 2007;21(10):2225–6.

    Article  CAS  PubMed  Google Scholar 

  76. Ma SY, Au WY, Chim CS, Lie AKW, Lam CCK, Tse E, et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol. 2004;124(6):754–61.

    Article  CAS  PubMed  Google Scholar 

  77. Costa RO, Bellesso M, Chamone DAF, Ruiz MA, Neto AEH, Aldred VL, et al. T-cell large granular lymphocytic leukemia: treatment experience with fludarabine. Clinics. 2012;67(7):745–8.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, et al. CD52 expression in T-cell large granular lymphocyte leukemia - implications for treatment with alemtuzumab. Leuk Lymphoma. 2005;46(5):723–7.

    Article  CAS  PubMed  Google Scholar 

  79. Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, et al. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematol. 2016;3(1):e22–9. https://doi.org/10.1016/S2352-3026(15)00227-6.

    Article  PubMed  Google Scholar 

  80. Subbiah V, Viny AD, Rosenblatt S, Pohlman B, Lichtin A, Maciejewski JP. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol. 2008;36(9):1078–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Litam PP, Friedman HD, Loughran TP Jr. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med. 1993;118(12):954–5. https://doi.org/10.7326/0003-4819-118-12-199306150-00007.

    Article  CAS  PubMed  Google Scholar 

  82. Lamy T, LePrise PY, Amiot L, Drenou B, Fauchet R, Genetet N, Semana G. Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia. Blood. 1995;85(11):3352–3.

    Article  CAS  PubMed  Google Scholar 

  83. Morris JC, Janik JE, White JD, Fleisher TA, Brown M, Tsudo M, et al. Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2006;103(2):401–6.

    Article  CAS  PubMed  Google Scholar 

  84. Waldmann TA, Conlon KC, Stewart DM, Worthy TYA, Janik JE, Fleisher TA, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013;121(3):476–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Frohna PA, Ratnayake A, Doerr N, Basheer A, Al-Mawsawi LQ, Kim WJ, et al. Results from a first-in-human study of BNZ-1, a selective multicytokine inhibitor targeting members of the common gamma (γc) family of cytokines. J Clin Pharmacol. 2020;60(2):264–73.

    Article  CAS  PubMed  Google Scholar 

  86. O’Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with t-cell malignancies. Clin Cancer Res. 2009;15(7):2514–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, et al. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008;112(12):4694–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, et al. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016;34(3):430–42.

    PubMed  Google Scholar 

  89. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.

    Article  CAS  PubMed  Google Scholar 

  90. Bilori B, Thota S, Clemente MJ, Patel B, Jerez A, Afable M, et al. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia. 2015;29(12):2427–9.

    Article  CAS  PubMed  Google Scholar 

  91. Pelliccia S, Di Napoli A, Naso V, Alma E, Rebecchini C, Cox MC. Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment. Eur J Haematol. 2013;91(2):183–6.

    Article  PubMed  Google Scholar 

  92. Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019;52(7):415–23. Comprehensive reviews on the role of STAT3 in cancer and present inhibitors of STAT3 signaling cascades.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Andrea Rivero was supported by a “Emili Letang-Josep Font” grant (Hospital Clinic de Barcelona).

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Clínic, Barcelona, Spain

    Laura Magnano & Andrea Rivero

  2. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Laura Magnano

  3. Hematopathology Unit, Department of Pathology, Hospital Clínic, Barcelona University, Villarroel, 170, 08036, Barcelona, Spain

    Estella Matutes

Authors
  1. Laura Magnano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Rivero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Estella Matutes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Estella Matutes.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Leukemia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Magnano, L., Rivero, A. & Matutes, E. Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment. Curr Oncol Rep 24, 633–644 (2022). https://doi.org/10.1007/s11912-021-01159-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-021-01159-y

Keywords

Search

Navigation